Public Health Administration

Cathy A. Raevsky, Director
Andy Miller, M.D., Health Officer

202 Mira Loma Drive
Oroville, California 95965

T: 530.552.4000
F: 530.538.2164

buttecounty.net/publichealth

Standing Orders for Supply of Ondansetron (Zofran) for Shelter Residents

Trade Name	Zofran, Zuplenz, and Zofran ODT
Presentation	Tablets: 4 mg and 8 mg Or Orally Disintegrating Tablets: 4 mg and 8 mg Or Oral Solution: 4 mg/5 mL
Indication	Relief of nausea and / or vomiting
Contraindications	Patients known to have hypersensitivity (e.g., anaphylaxis) to ondansetron or any components of the formulation. Concomitant use of apomorphine.
Warnings and Precautions	Hypersensitivity reactions including anaphylaxis and bronchospasm: • Discontinue ZOFRAN if suspected. Monitor and treat promptly per standard of care until signs and symptoms resolve. QT interval prolongation and Torsade de Pointes: • Avoid in patients with congenital long QT syndrome; monitor with electrocardiograms (ECGs) if concomitant electrolyte abnormalities, cardiac failure or arrhythmias, or use of other QT prolonging drugs. Serotonin syndrome: • Reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. If such symptoms occur, discontinue ZOFRAN and initiate supportive treatment. If concomitant use of ZOFRAN with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome. Masking of progressive ileus and/or gastric distention following abdominal surgery or chemotherapy-induced nausea and vomiting: • Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction.

Turn Over

	Phenylketonuric patients should be informed that ZOFRAN ODT orally disintegrating tablets contain phenylalanine (a component of aspartame). Each 4-mg and 8-mg orally disintegrating tablet contains less than 0.03 mg phenylalanine.
Dose	Adults and children ≥ 4 years • 4mg single dose (tablet or wafer) if no response, give another 4 mg dose
Dose Frequency	Maximum dose is 8 mg three times in 24 hours
Administration	Orally Disintegrating Tablets • Do not attempt to push ZOFRAN ODT tablets through the foil backing. With dry hands, PEEL BACK the foil backing of 1 blister and GENTLY remove the tablet. IMMEDIATELY place the ZOFRAN ODT tablet on top of the tongue where it will dissolve in seconds, then swallow with saliva. Administration with liquid is not necessary. Or Tablet • Orally
Storage	Must be stored out of patient and public access, preferably in a locked room or a locked cabinet securely attached to the wall or floor
Adverse Effects	The most common adverse reactions in adults are: • headache, malaise/fatigue, constipation, diarrhea.
Nursing	Check for relief of nausea and vomiting after administration of the first 4mg dose. If no relief, can administrate another 4mg dose.
Documentation	Administration record is to be documented by the administering nurse. Document on the Medical Administration Registration (MAR). The record of administration must be checked and countersigned by a medical officer within 24 hours of initial administration

Dr. Andrew Miller

11/16/2018
Date

Turn Over